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Abstract
Background: Angiogenesis is an essential process in endometriosis disease progression. Earlier, we demonstrated
that anti-angiogenic peptide, ABT-898 prevents neoangiogenesis of human endometriotic lesions in a xenograft
mouse model. Since angiogenesis is essential for normal ovarian and uterine function, we evaluated effects of
ABT-898 on normal female reproductive processes in mice.
Methods: Cycling female C57BL/6N mice were dosed with ABT-898 (100 mg/kg) or 5 % dextrose control for 21
consecutive days to cover multiple estrous cycles (average estrous cycle 4 to 5 days in mice). Pregnant female mice
were dosed with ABT-898 (100 mg/kg) or control on alternate days over the course of gestation, beginning at
gestation day 7.5 to 17.5 (gestation length 21 days). Histological analysis along with CD31 and Vimentin
immunohistochemistry were performed on ovaries and uteri obtained from treated and control mice. To
understand the influence of ABT-898 on systemic angiogenic factors, a Pro Mouse Cytokine 9-plex assay was
performed on plasma samples obtained from mice prior to treatment, during the second week of ABAT-898 or
control treatment and on the last day of treatment.
Results: ABT-898 did not affect the number of estrous cycles over the 21 day treatment compared to control.
Histological analysis of ovaries found no difference in the number of primordial, primary, secondary, and antral
follicles between ABT-898 treated and control groups. Similarly, no difference was observed in the microvessel
density between ABT-898 treated and control uteri, ovarian follicles or corpus luteum when assessed using CD31 or
vimentin immunohistochemistry. Electron microscopy revealed similar capillary structure and appearance in both
ABT-898 treated and control uteri. Although peripheral blood angiogenic cytokine profiles (IL-15, IL-18, M-CSF, b-FGF,
PDGF-bb, MIG, MIP-2, LIF and VEGF) changed over the course of the intervention, there was no significant difference
between ABT-898 and control groups at any of the studied time points. Treatment with ABT-898 during pregnancy
had no effect on litter size at birth, pup weight at birth or pup weight at weaning.
Conclusion: Our findings suggest that ABT-898 may not alter angiogenesis dependent reproductive processes in
female mice. However, an extensive reproductive toxicology screening is required to substantiate use of ABT-898 in
future.
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Background
Endometriosis, the growth of endometrial glands and
stroma outside of the uterus, is a disease that causes
dyspareunia, dysmenorrhea, and pelvic pain. Retrograde
menstruation [1] the movement of menstruating endo-
metrial tissue from the uterus through the fallopian
tubes, and into the peritoneal cavity is a widely accepted
explanation for the presence of endometrium in an ec-
topic location [2]. Other theories include the coelomic
metaplasia that postulates endometriosis arises from the
metaplasia of cells lining the visceral and abdominal
peritoneum and stem cell theory suggesting contribu-
tions from endometrial stem/progenitor cells and bone
marrow-derived stem cells in the pathogenesis of endo-
metriosis. The formation and survival of endometriosis
lesions requires the development of a complex vascular
network to meet the metabolic demands of the growing
tissue. This is achieved by angiogenesis, the formation of
new blood vessels from pre-existing blood vessels
(reviewed in [3]). Hence, anti-angiogenic therapy is a po-
tential promising way to medically manage endometri-
osis disease progression.
Angiogenesis is also essential to female reproduction.
In seminal work done by Klauber et al. 1997, and
Zimmerman et al., 2003, it was demonstrated that in-
hibition of angiogenesis in non-pregnant cycling fe-
male mice stopped endometrial maturation, corpora
luteal formation and gonadotropin mediated follicle
development. Inhibition of angiogenesis in pregnant
female mice caused impaired decidualization, placen-
tal formation, and resulted in embryo resorption [4].
Although several anti-angiogenic compounds have
been effective in limiting neovascularization of endo-
metriotic lesions in animal models (reviewed in [5, 6]), few
have been assessed for their potential negative impacts on
female reproduction [7].
Thrombospondin-1 (TSP-1), an endogenous inhibitor
of angiogenesis, is part of the large thrombospondin
family of extracellular matrix glycoproteins [8]. It pri-
marily affects angiogenesis by binding to CD36 on
endothelial cells, inhibiting proliferation [9] and indu-
cing apoptosis [10]. It also binds and sequesters vas-
cular endothelial growth factor (VEGF), the primary
pro-angiogenic growth factor, limiting its bioavailabil-
ity [11, 12]. Using an alymphoid xenograft mouse
model [13], we have previously demonstrated that the
anti-angiogenic peptide ABT-898, a thrombospondin-1
(TSP-1) mimetic, prevents the neovascularization of
human endometriotic lesions in mice. Mice that had
previously been treated with ABT-898 were able to
become pregnant, had normal decidual and placental
morphology, and litter sizes indicating no lasting ef-
fects of ABT-898 on female reproduction. It was essential
for us to confirm that ABT-898 was functioning to reduce
lesion vascularization before proceeding to pregnancy
trials.
Since angiogenesis is integral in normal physiological
processes, in this study we examined the chronic effect
of ABT-898 on angiogenesis dependent reproductive
processes in both non-pregnant cycling and pregnant fe-
male mice. We found no evidence that ABT-898 affects
endometrial or ovarian structure and function in non-
pregnant cycling female mice, or litter size and pup
weight of pregnant female mice.
Methods
Experimental design
Female C57BL/6N mice (Charles River Laboratories
International, Wilmington, MA, USA), 8-weeks old were
given daily 100 μL intraperitoneal injections (n = 11) of
100 mg/kg ABT-898 (Abbott Laboratories, Abbott Park,
IL, USA) in 5 % dextrose (Baxter Corporation, Toronto,
ON, Canada), or 100 μL of 5 % dextrose as a control
(n = 11) for 21 days. After the treatment period, mice
from ABT-898 treated (n = 8) and 5 % dextrose con-
trol (n = 8) groups were sacrificed, and their repro-
ductive organs were processed for histology or
electron microscopy. ABT-898 treated (n = 3) and 5 %
dextrose control (n = 3) mice were also placed into
breeding pairs. After the detection of a copulation
plug, female mice were determined to be at gestation
day 0.5. Pregnant mice were then dosed with ABT-
898 or 5 % dextrose on gestation day 7.5, 9.5, 11.5,
13.5, 15.5, and 17.5. Timing for treatment during
pregnancy was chosen to cover the window of im-
portant landmarks such as early placental develop-
ment and immune cell enrichment as well as
placental circulation. At parturition litter size and pup
weight were measured, and pup weight was measured
again at weaning. In order to address whether admin-
istration of ABT-898 before coitus would have any
impact on the pregnancy outcomes, we performed
additional set of experiments. Female C57BL/6N mice
(8 week old) were treated with ABT-898 (n = 3) or
5 % Dextrose (n = 3) for 2 days (1 injection/day) and
breeding pairs were set after the second injection.
After detection of copulation plug, mice were injected
daily with ABT-898 or 5 % dextrose intraperitoneally
from gestation day 0.5 to 6.5 (gestation day 0.5 de-
notes presence of copulation plug). Mice were sacri-
ficed on gestation day 7.5 for visualization and
quantification of implantation sites.
Vaginal cytology
In order to monitor the estrous cycle in ABT-898 treated
and 5 % dextrose control groups, vaginal smears were
collected from each mouse over the 21 day treatment
period. 21 days were chose to determine impact of ABT-
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898 on multiple estrous cycles (average estrous cycle in
mice 4–5 days). In brief, the vaginal contents were aspi-
rated with 45 μL of PBS, which were then placed in
15 μL drops on a glass slide, and left to dry at room
temperature. Dried smears were fixed with 70 % ethanol,
rehydrated in deionized water, and then briefly stained
with hematoxylin (Gill’s Method, Fisher Chemicals, Fair
Lawn, NJ, USA), rinsed in tap water, and stained with
1 % eosin Y (Electron Microscopy Sciences, Hatfield,
PA, USA). Smears were dehydrated in increasing con-
centration of ethanol, cleared in xylenes, and cover-
slipped using Permount (Electron Microscopy Sciences,
Hatfield, PA, USA). Stage of the estrous cycle was deter-
mined by comparing the abundance of cornified epithe-
lial cells, nucleated epithelial cells, and leukocytes as
described in [14].
Ovarian follicle counts
Paraformaldehyde fixed, paraffin embedded ovaries
were sectioned at 5 μm and mounted on glass slides.
Sections were deparaffinised using xylenes rehydrated
using decreasing concentrations of ethanol, and then
stained with hematoxylin and eosin as already de-
scribed. In every tenth section the numbers of folli-
cles were counted using a modified Pedersen and
Peter’s classification system [15]. Only follicles that
had a visible nucleus in the oocyte were counted. Fol-
licles were classified primordial if they had a single
layer of squamous granulosa cells. Primary follicles
contained a single layer of cuboidal granulosa cells,
secondary had two or more granulosa cell layers, and
antral follicles had a visible antrum.
Immunohistochemistry of uteri and ovaries
Paraformaldehyde fixed, paraffin embedded uteri and
ovaries were sectioned at 5 μm and mounted on glass
slides. Following deparaffinisation and rehydration, anti-
gen retrieval was conducted using 0.01 M sodium citrate
buffer (pH 6.0) in a hot water bath at 95 °C for 15 min.
Endogenous peroxidase activity was blocked using 0.3 %
hydrogen peroxide in PBS for 30 min at room
temperature. Sections were blocked with 1 % bovine
serum albumin in PBS for 45 min at room temperature.
Primary antibody incubation (rabbit anti-mouse CD31-
ab28364, or rabbit anti-mouse vimentin-ab92547, Abcam
Inc., Toronto, ON, Canada) occurred overnight at 4 °C at
a 1/500 dilution. Isotype antibody served as a negative
control. Sections were incubated in bioinylated goat anti-
rabbit secondary (1/2000 dilution, DAKO, Markham, ON,
Canada) at room temperature for 60 min, then 1/4000
Extravadin-Peroxidase (Sigma Life Sciences, Oakville, ON,
Canada) for 30 min at room temperature. Sections were
stained with DAB+ Liquid Chromagen Substrate System
(DAKO, Markham, ON, Canada) for two minutes, rinsed
in deionized water, counterstained with hematoxylin
(Gill’s Method), rinsed in tap water and then dehy-
drated, cleared and coverslipped as previously de-
scribed. A semi-quantitative assessment of CD31(+)
microvessel densities was done using ImageJ Pro Plus
software version 6.0 (NIH, Bethesda, MD). The inte-
grated optical density expressed in arbitrary units was
calculated in three fields of view per tissue type from
each animal.
Murine peripheral blood plasma cytokine analysis
The cytokines IL-15, LIF, M-CSF, b-FGF, PDGF-bb,
MIG, MIP-2, IL-18 and VEGF were measured in periph-
eral blood plasma using a Bioplex Pro Mouse Cytokine
Group II panel 9 plex assay on a Bio-Plex 200 suspen-
sion system (both from Bio-rad Laboratories, Hercules,
CA, USA) as per manufacturer’s instructions. Peripheral
blood plasma was collected as previously described [13]
prior to treatment, during the second week of treatment
with ABT-898 or 5 % dextrose control, and on the last
day of treatment. 15 μL of plasma per sample was used
in the assay. Samples were diluted 4-fold. 100 μL of
assay buffer and 50 μL of beads were added to the assay
plate. After washing twice with 100 μL of wash buffer,
50 μL of sample was added to each well. Following 1-hour
incubation (in the dark with shaking at 300RPM) wells
were washed 3 times with 100 μL of wash buffer prior to
adding 25 μL of detection antibody. Samples were incu-
bated for 30 min then washed 3 times. 50 μL of
streptavidin-PE was added to each well and was incubated
for 10 min. After 3 wash steps, beads were resuspended in
125 μL of assay buffer, and shaken at 1100RPM for 30 sec-
onds. The plate was read using Bio Plex 200 Suspension
Array System.
Statistical analysis
All data were analyzed using Sigma Stat 3.0 software
(Systat Software, San Jose, CA, USA). Ovarian follicle
counts, estrous cycles, microvessel densities and preg-
nancy outcomes data were analyzed using a Student’s T-
Test, while peripheral blood cytokine levels where com-
pared using a repeated measures one way ANOVA.
Results
The effect of ABT-898 on angiogenesis dependent
reproductive processes in non-pregnant female mice
Prior to the study, to confirm that each lot of the
thrombospondin-1 mimetic peptide ABT-898 had anti-
angiogenic properties, we performed in vitro angiogen-
esis assays as previously described [13]. ABT-898 was
able to completely ameliorate endothelial cell tube
formation in vitro (data not shown). Non-pregnant cyc-
ling female mice were treated for 21 consecutive days
with ABT-898 at a concentration (100 mg/kg) that had
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previously been shown to reduce neovascularization of
endometriosis lesions [13], or 5 % dextrose control.
Vaginal cytology was analyzed each day to assess the
effect of ABT-898 on the estrous cycle. Mice showed
the classical stages of the estrous cycle irrespective of
treatment (representative vaginal cytology for ABT-
898 Fig. 1a–e, 5 % dextrose control 1 F–J). The total
number of estrous cycles did not differ between ABT-
898 treated (3.75 cycles) and 5 % dextrose control
groups (3.3 cycles, Fig. 1k, p = 0.561).
After the 21 day treatment period mice were sacrificed
and reproductive tracts were harvested for histological
analysis. No gross differences were seen at this point in
the size, structure, or vascularity of the reproductive
tracts between ABT-898 (Fig. 1l), and control (Fig. 1m)
groups. In an attempt to assess the effect of ABT-898 on
follicular development, an angiogenesis dependent
process, we performed follicle counts on ovaries from
ABT-898 and control mice. There were no observable
differences in the microscopic anatomy of the ovaries
between ABT-898 (Fig. 2a) and control (Fig. 2b) groups.
Using a modified version of Pederson’s and Peter’s classi-
fication system we counted the number of primordial,
primary, secondary and antral follicles (representative
follicle histology Fig. 2c–j), and found no difference be-
tween ABT-898 and control groups (Fig. 2k). These re-
sults provide initial evidence that ABT-898 does not
disrupt the estrous cycle or follicular development in
mice after a chronic daily treatment for 21 days.
The effect of ABT-898 on blood vessel development and
structure in reproductive organs of female mice
We next investigated whether ABT-898 would reduce
the blood vessel density, or alter endothelial cell
structure in organs where physiological angiogenesis
occurs, the uterus and the ovary. We performed im-
munohistochemistry for CD31, a pan endothelial cell
marker, on ovarian and uterine sections. Semi-
quantitative analysis of uterine sections found no dif-
ference in the number of CD31 (+) blood vessels be-
tween ABT-898 (Fig. 3a) and control (Fig. 3b) groups
(p = 0.65, Fig. 3i). We also analyzed CD31 (+) blood
vessels in antral follicles, and found no difference in
the number or structure of blood vessels from ABT-
898 (Fig. 3c, d) compared to control (Fig. 3f, g)
groups (p = 0.803, Fig. 3i). Immunohistochemistry for
vimentin, an intermediate filament expressed in cells
of mesenchymal origin, was used to investigate cor-
pora lutea. Qualitative observations found no differ-
ence in the size and structure of the corpora lutea
between ABT-898 (Fig. 3e) and control (Fig. 3h)
groups. Although vimentin is expressed in other cell
types of the corpus luteum besides endothelial cells,
blood vessels are easily identified using this stain and
the numbers were similar between ABT-898 (Fig. 3e)
and control (Fig. 3h) groups.
We next wanted to evaluate effect of ABT-898 on the
ultra-structure of endothelial cells in reproductive organs
using transmission electron microscopy. No obvious
Fig. 1 ABT-898 does not affect the estrous cycle in female mice. Representative vaginal cytology of the estrous cycle in mice dosed with ABT-898
(a–e) or 5 % dextrose (f–j). Keratinized epithelial cells (a, f) indicative of estrous were used to denote the start of a new estrous cycle. The number
of estrous cycles did not significantly differ between ABT-898 and 5 % dextrose groups (3.6 vs 3.3, p = 0.561) over the course of the 21 day dosing
period (k). Female reproductive tracts from mice dosed with ABT-898 (l) or 5 % dextrose (m). Gross observations indicated that female reproductive
tracts from ABT-898 (l) treated mice did not differ from 5 % dextrose control in size (m), morphology or vascularity. Images (a–j) are magnified 400×
and scale bars represent 75 μm
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differences were seen in endothelial cells of capillary sized
blood vessels of the uterus between ABT-898 (Additional
file 1: Figure S1A), and control groups (Additional file 1:
Figure S1B). Similar observations were made in the ovary
(data not shown).
Effect of ABT-898 on murine angiogenic cytokines in
peripheral blood
In an attempt to assess how ABT-898 affected angio-
genesis on a systemic level, we evaluated expression
of angiogenic cytokines in peripheral blood plasma
over the course of the 21 day treatment using Bioplex
Pro Mouse Cytokine Group II panel 9 plex angiogen-
esis assay. Although expression of some of the cyto-
kines (LIF Fig. 4b; b-FGF Fig. 4d; MIP-2 Fig. 4g;
VEGF Fig. 4i) differed between time points there was
no statistically different expression of cytokines be-
tween ABT-898 and control groups. Taken together,
these results provide preliminary evidence that ABT-
898 does not impede physiological angiogenesis in the
mouse ovary or uterus.
The effect of ABT-898 on pregnancy outcomes
Blood vessel growth, initially through vasculogenesis and
later through angiogenesis, is essential during pregnancy.
We have previously shown that female mice treated with
ABT-898 prior to pregnancy had normal litters and pla-
cental structures [13]. Here we wanted to establish what
effect ABT-898 would have on pregnancy if it was
injected chronically over the course of mouse gestation.
Female mice treated with ABT-898 on alternate days
over the course of gestation, beginning at gestation day
7.5, had the same litter size (Fig. 5a), pup weight at birth
(Fig. 5b), and pup weight at weaning (Fig. 5c) as con-
trols. These results provide initial evidence that ABT-
898 does not affect pregnancy outcomes. Similarly, in
mice treated 2 days before coitus with ABT-898 and 5 %
dextrose control, allowed to get pregnant and continued
treatment from gestation day 0.5 to 6.5, had comparable
numbers of implantation sites between ABT-898 treated
and control groups. The implantation sites in 3 ABT-
898 treated mice were 7, 9 and 8. Implantation sites in 3
control mice were 9, 10 and 7. We did not observe any
Fig. 2 ABT-898 does not alter the number of ovarian follicles. Ovaries from mice dosed with ABT-898 (a) or 5 % dextrose (b) were sectioned and
the numbers of primordial (c, g), primary (d, h), secondary (e, i) and antral (f, j) follicles were counted. The number of primordial, primary, secondary
and antral follicles did not significantly differ between ABT-898 and 5 % dextrose groups (k). Red arrow: primordial follicle, black arrow: primary follicle,
green arrow: secondary follicle, yellow arrow: antral follicle. Scale bar represents 75 μm. P < 0.05
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abnormalities in the gross examination of implantation
sites between ABT-898 and control treated mice.
Discussion
Endometriosis is a gynecological disease affecting fe-
males of child bearing age. It causes dysmenorrhea, dys-
pareunia, pelvic pain, and is associated with infertility
[16]. Current therapeutic strategies to manage endomet-
riosis are aimed at limiting lesion growth by preventing
ovarian steroid production, and by surgical removal of
lesions. These strategies often provide unsatisfactory re-
sults as recurrence rate is high after surgery (reviewed in
[17]), and inhibition of ovarian steroid production does
not improve fecundity [18]. New strategies are needed to
manage endometriosis that limits disease progression,
without affecting fertility [19]. Angiogenesis, essential in
the pathogenesis of macular degeneration, diabetic retin-
opathy, rheumatoid arthritis, and cancer (reviewed in
[20]), is also necessary for the growth and survival of
endometriosis lesions. Several anti-angiogenic compounds
Fig. 3 CD31 and vimentin immunohistochemistry of ABT-898 treated and 5 % dextrose control uteri and ovaries. Semi-quantitative analysis
of CD31+ blood vessels in the endometrium found no significant difference (p = 0.45, i) between ABT-898 (a) and 5 % dextrose (b) groups.
Immunohistochemistry for CD31 also found that blood vessel development around antral follicles was not altered by ABT-898 (c, f, d, g), and
semi-quantitative analysis found no significant difference (p = 0.75). Vimentin immunohistochemistry showed no difference in structure or number of
microvessels (green arrows) between ABT-898 (e) and 5 % dextrose (h) corpus luteum. Scale bars represent 75 μm. FOV: Field of view
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Fig. 4 Peripheral blood plasma cytokine profiles in cycling female mice dosed with ABT-898 or 5 % dextrose control. Peripheral blood plasma
levels of IL-15 (a), IL-18 (b), M-CSF (c), b-FGF (d), PDGF-bb (e), MIG (f), MIP-2 (g), LIF (h) and VEGF (i) did not significantly differ over the duration
of the intervention or between ABT-898 and 5 % dextrose groups. PT: Pre-treatment, TW2: Treatment Week 2, CW2: Control Week 2, TW3:
Treatment Week 3, CW3: Control Week 3
Fig. 5 Effect of ABT-898 on mouse pregnancy outcomes. Treatment with ABT-898 on every other gestation day beginning at gestation day 7.5
did not significantly alter litter size (a, p = 0.802), pup weight at birth (b, p = 0.560), or pup weight at weaning (c, p = 0.99)
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limit the neovascularization of endometriosis in animal
models; however their effects on fecundity have been
poorly investigated. In this study we have demonstrated
that the anti-angiogenic TSP-1 mimetic peptide, ABT-898,
does not affect female mouse fertility when given chronic-
ally prior to pregnancy, or when administered during ges-
tation. In addition, we have shown that ABT-898 does not
affect the microvessel density in the ovary and uterus,
where angiogenesis is essential to normal function.
Previous studies assessing the effect of ABT-898 on
folliculogenesis in vivo using marmoset monkeys (Calli-
thrix jacchus) had similar results [21]. The authors
found no effect on the ovulatory cycle, and ABT-898 did
not induce luteolysis [21]. Although, they saw a decrease
in the number of proliferating endothelial cells in the
follicles of ABT-898 treated ovaries, we did not notice
any significant difference in the endothelial cells (data
not shown). Our results indicate that ABT-898 did not
affect microvessel density between ABT-898 treated ver-
sus control. Other reports have demonstrated that anti-
angiogenic compounds are compatible with female
reproduction. Becker et al., 2005 demonstrated that
endostatin, an endogenous inhibitor of angiogenesis
formed by the site specific cleavage of collagen XVII did
not inhibit the estrous cycle, ovarian steroid production,
or corpus luteum formation providing further evidence
that anti-angiogenic therapies are compatible with preg-
nancy, at least in mouse models. While that study dem-
onstrated that endostatin is compatible with female
reproduction, we demonstrate for the first time that an
anti-angiogenic agent does not reduce the blood vessel
density in reproductive organs. Endostatin has a similar
mechanism of action as TSP-1; both inhibit endothelial
cell proliferation, induce endothelial cell apoptosis, and
bind and sequester VEGF (reviewed in [22]). The similar
biological properties could explain why these peptides
are compatible with pregnancy, while other anti-
angiogenic compounds (sFLT-1; [23], TNP-470; 4), com-
pletely inhibit female reproduction. Further research into
why some anti-angiogenic compounds affect female
reproduction, while others are compatible with preg-
nancy is needed.
We have measured pro-angiogenic cytokines including
VEGF, a major controller of angiogenic processes, in sys-
temic circulation and did not find significant differences
in any of the cytokines over the period of treatment with
ABT-898. TSP-1 is known to sequester VEGF and re-
duce its bioavailability [11], recently, Campbell et al.
2011 reported decreased levels of VEGF in the tumors
from mice treated with ABT-898 treatment in a mouse
model of epithelial ovarian cancer. It is possible that
ABT-898 affects VEGF specifically at inflammatory sites
or tumors [24] where hypoxia drives overproduction
and results in imbalance in several angiogenic factors
including VEGF. In normal cycling female mice, we
observed similar levels of VEGF in systemic circula-
tion between treatment and control suggesting that
ABT-898 may not affect VEGF and other pro-
angiogenic cytokines systemically. We have previously
shown that alymphoid mice induced with endometri-
osis and treated for 21 days with ABT-898 were able
to get pregnant at the end of the ABT-898 treatment
[25]. Further treatment of alymphoid mice during
pregnancy with ABT-898 did not impact litter size
outcome or litter weight [25], supporting the notion
that ABT-898 inhibit vascularization of endometriotic
lesions without impacting reproductive outcomes in
alymphoid mouse model of endometriosis [25].
We have proposed previously [13, 25] that the differ-
ence in blood vessel structure between endometriotic le-
sions and reproductive organs could explain why ABT-
898 reduces neovascularization of endometriotic lesions,
while not affecting angiogenesis in the uterus or ovary.
Vasculature in pathological situations, such as endomet-
riosis ( [26], Additional file 2: Figure S2A) and cancer
[27], grow in a chaotic and disorganized manner, com-
pared to the structured physiological neovascularization
in reproductive organs (Additional file 2: Figure S2B, C).
Vessels in pathological situations fail to recruit mural
cells (pericytes and vascular smooth muscle cells), which
provide structural support and pro-survival stimuli to
endothelial cells [28]. However, we did not carry any ex-
periments to substantiate whether endometriotic lesions
indeed have issues related to pericyte recruitment and
vascular stability. Although speculative, it is plausible
that in the absence of mural cells, endothelial cells are
more susceptible to the anti-angiogenic effects of ABT-
898, compared to blood vessels in the uterus and ovary
where mural cells are abundant. In this study we looked
at the ultrastructure of capillary sized blood vessels in
the uterus and ovary of mice treated with ABT-898. We
found no difference in the ultrastructure of blood vessels
between ABT-898 and control groups, giving some
evidence that the structure and organization of blood
vessels in reproductive organs may protect them
against the anti-angiogenic effects of ABT-898. While
our study provides some insights into the effects of
ABT-898 on physiological angiogenesis during mouse
estrous cycle and pregnancy, there are certain limita-
tions. The sample size in the current study is small
that limits scope of interpretations. Our data does not
reveal why and how ABT-898 affects angiogenesis of
endometriotic lesions without impacting physiological
angiogenesis in the ovary and uterus. In order to de-
lineate whether ABT-898 impacts ovarian follicular
development and corpus luteum function, future work
needs to be carried out in immature or hypophysectomized
mice.
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Conclusion
In summary, we demonstrate for the first time that
chronic administration of ABT-898 does not impact fe-
male mouse fertility. ABT-898 had no effect on the es-
trous cycle, ovarian follicle counts, vascularization of the
uterus or ovary, or litter size and pup weight at birth.
These results provide further evidence that ABT-898
may be used as a novel therapeutic agent to manage
endometriosis disease progression, as it prevents neovas-
cularization of endometriotic lesions while not affecting
female fertility. However, an extensive reproductive toxi-
cology studies are warranted in multiple species before
ABT-898 can be considered for usage in human endo-
metriosis. Our results provide first of the many steps to-
wards evaluating ABT-898 as a future therapeutic for
endometriosis.
Supplemental methods
Electron microscopy of the non-pregnant uterus: Tissues
were fixed by immersion in 2 % paraformaldehyde,
0.1 M sucrose and 2.5 % glutaraldehyde in PBS over-
night at 4 °C. Tissues were washed five times in PBS for
one minute, and then incubated in 1 % osmium tetrox-
ide (Electron Microscopy Sciences, Hatfield, PA, USA)
for 60 min at room temperature. Samples were thor-
oughly washed in PBS, then deionized water before de-
hydration in increasing concentrations of ethanol, and
cleared with propylene oxide (Electron Microscopy
Sciences, Hatfield, PA, USA). Sections were embedded
in EMbed 812 epoxy resin (Electron Microscopy
Sciences, Hatfield, PA, USA), which was polymerized at
60 °C for 36 hours. Samples were cut into ultrathin sec-
tions, mounted on formvar-coated nickel grids and
stained with uranyl acetate and lead citrate. Final sec-
tions were examined using transmission electron mi-
croscopy (Hitachi 7000).
Whole mount immunofluorescence: Blood vessel struc-
ture of human endometriotic lesions, non-pregnant
mouse uteri and ovaries was visualized using whole
mount immunofluorescence (technique initially de-
scribed in [29]) for CD31. Human endometriotic lesions
were engrafted in alymphoid mice as previously de-
scribed [13, 25]. Non-pregnant uteri and ovaries were
from female C57BL/6N mice. In brief, tissues were har-
vested from sacrificed mice, sectioned into 1 mm3 pieces
and fixed in 90 % methanol for two hours on ice. Sec-
tions were washed in PBS (containing 1 % bovine serum
albumin (BSA), 0.1 % sodium azide and 0.3 % Triton X-
100), and then incubated overnight in primary antibody
(Rat anti-Mouse CD31-PE, or Mouse anti-Human CD31,
both at a 1/100 dilution, BD Biosciences, Mississauga,
ON, Canada) at 4 °C. The following day sections were
washed twice: first in PBS (containing 1 % BSA, 0.1 %
sodium azide and 0.3 % Triton X-100), followed by a
subsequent wash in PBS (containing 1 % BSA and 0.1 %
sodium azide). Sections were transferred to a microscope
slide, coverslipped and photographed with an epifluores-
cence microscope using AxioVision SE64 Rel. 4.8 (Carl
Zeiss Canada Ltd., Toronto, ON, Canada).
Additional files
Additional file 1: Figure S1. (A-B)Transmission electron microscopy of
non-pregnant endometrium. Ultrastructural assessment of capillary sized
blood vessels in the endometrium found no obvious differences between
ABT-898 (A) and 5 % dextrose groups (B). Images (A-B) are magnified
3500×. (TIF 174 kb)
Additional file 2: Figure S2. Whole mount immunofluorescence for
the pan endothelial cell marker CD31 in endometriotic lesions, uterus
and ovary. (A) Endometriotic lesions have a robust, disorganized vascular
network. (B) The mouse ovary is highly vascularized, but the blood
vessels have a more uniform appearance, and an even distribution
throughout the organ compared to an endometriotic lesion. (C)
Anti-mesometrial view of the mouse uterus. The myometrium contains
few blood vessels compared to the endometrium, which is also highly
vascularized. Images are magnified 100× and scale bars represent 100 μm.
AMM: Anti-mesometrial myometrium; AME: Anti-mesometrial
endometrium. (TIF 510 kb)
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